following an abbreviated submission:
bimekizumab (Bimzelx®) is accepted for restricted use within NHSScotland.
Indication under review: alone or in combination with methotrexate, for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs).
SMC restriction: Use in patients with active psoriatic arthritis who have not responded adequately to two conventional DMARDs, given either alone or in combination.
Bimekizumab offers an additional treatment choice of in the therapeutic class of interleukin inhibitors for this indication.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
Download detailed advice639KB (PDF)
Medicine details
- Medicine name:
- bimekizumab (Bimzelx)
- SMC ID:
- SMC2605
- Indication:
Alone or in combination with methotrexate (MTX), is anticipated to be indicated for the treatment of active psoriatic arthritis (PsA) in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs).
- Pharmaceutical company
- UCB Pharma Ltd
- BNF chapter
- Musculoskeletal and joint diseases
- Submission type
- Abbreviated
- Status
- Restricted
- Date advice published
- 13 November 2023